Prelude Therapeutics Inc (PRLD) revealed Loss for third quarter that decreased from the same period last year and beat the Street estimates.
The company's bottom line came in at -$19.73 million, or -$0.26 per share. This compares with -$32.27 million, or -$0.43 per share, last year.
Analysts on average had expected the company to earn -$0.35 per share. Analysts' estimates typically exclude special items.
The company's revenue for the period rose 116.7% to $6.50 million from $3.00 million last year.
Prelude Therapeutics Inc earnings at a glance (GAAP) :
-Earnings: -$19.73 Mln. vs. -$32.27 Mln. last year.-EPS: -$0.26 vs. -$0.43 last year.-Revenue: $6.50 Mln vs. $3.00 Mln last year.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.